Studies, using in vivo microdialysis, on the effect of the dopamine uptake inhibitor GBR 12909 on 3,4-methylenedioxymethamphetamine (ÔecstasyÕ)-induced dopamine release and free radical formation in the mouse striatum 
Administration to rats of the commonly misused recreational drug 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) results in both acute and long-term changes in the brain.
The major acute change observed is a large and rapid release of both 5-hydroxytryptamine (5-HT) and dopamine in specific brain regions. With regard to 5-HT, this has been demonstrated by the rapid decrease in tissue 5-HT content (Colado and Green 1994) , the use of in vivo microdialysis Gough et al. 1991; Gudelsky and Nash 1996; Mechan et al. 2001) and studies on the release of indoleamine from synaptosomal preparations . The release of dopamine has similarly been demonstrated by changes in tissue concentration (Schmidt et al. 1986; Colado and Green 1994) , microdialysis (Koch and Galloway 1997; Sabol and Seiden 1998; Colado et al. 1999) and in vitro techniques (Koch and Galloway 1997) .
The major long-term consequence of MDMA administration to rats is a sustained neurotoxic loss of 5-HT in several regions of the brain, characterized not only by a decrease in neurochemical parameters: [ (Stone et al. 1986; Schmidt 1987; Schmidt and Kehne 1990; Hewitt and Green 1994; Green et al. 1995; Colado et al. 1997 Colado et al. , 1999 , but also by histological evidence of damage (O'Hearn et al. 1988; Molliver et al. 1990 ). In contrast, no long-term damage to dopamine nerve terminals is seen after MDMA administration (Stone et al. 1986; Battaglia et al. 1987; Schmidt and Kehne 1990; Lew et al. 1996; Sabol et al. 1996; Colado et al. 1997 Colado et al. , 1999 .
While, in general, it appears to be true that all of the acute and long-term consequences of MDMA administration reported to occur in the rat also occur in several other species, including primates (Steele et al. 1994; Green et al. 1995) , a rather different pattern of effects of the drug is seen in the mouse.
Following MDMA administration to the mouse there is evidence of an acute release of 5-HT, as indicated by a rapid decrease in tissue 5-HTcontent . However, this change is modest compared with the change seen in rats (Colado and Green 1994) . There is also evidence of dopamine release, the striatal contents of dopamine and its metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) being reduced 3 h after the last of three doses of MDMA (30 mg/kg i.p., 3 h apart) .
The longer-term effect of MDMA in mice contrasts markedly with that seen in the rat. Basically, the cerebral 5-HT content is unaltered while the striatal dopamine concentration is substantially lowered (Stone et al. 1987; Battaglia et al. 1988; Logan et al. 1988; O'Callaghan and Miller 1994; O'Shea et al. 2001) . That is, the long-term effect of MDMA in mice is neurotoxic damage to dopamine, but not 5-HT, while the reverse is true in rats.
There have been rather few studies in mice on either the acute or long-term effects of MDMA and this contrasts strongly with the substantial number of studies in rats. Consequently, little is known about the mechanisms involved in the neurotoxic action of MDMA on dopaminergic neurones in the striatum. However, the observations that transgenic mice with high superoxide dismutase (SOD) activity were resistant to the neurotoxic action of MDMA (Cadet et al. 1995) and the fact that MDMA administration to mice caused decreased SOD activity, decreased glutathione peroxidase activity and increased lipid peroxidation in regions of the brain (Jayanthi et al. 1999) , do suggest that overproduction of free radicals probably plays a role in MDMA-induced neurodegeneration in mice as it does in rats Colado et al. , 1997 Sprague and Nichols 1995; Yeh 1999) .
Recently, we showed that while the dopamine uptake inhibitor GBR 12909 appeared to have little effect on MDMA-induced release of dopamine, it nevertheless prevented the long-term loss of striatal dopamine concentration . This result contrasts strongly with the fact that the 5-HT uptake inhibitor fluoxetine, administered to rats, inhibits both MDMA-induced 5-HT release and the subsequent neurotoxicity of 5-HT nerve endings (Schmidt 1987; Malberg et al. 1996; Sanchez et al. 2001) .
However, while the studies on the effect of fluoxetine on MDMA-induced release of 5-HT in the rat were the result of direct in vivo observations using microdialysis , the studies on the effect of GBR 12909 on MDMA-induced dopamine release in the mouse were indirect. That is, the assessment of dopamine release was made by subsequent measurement of dopamine and its metabolites in striatal tissue .
In order to clarify the action of MDMA on striatal dopamine release and the effect of GBR 12909 on that release we employed the technique of in vivo microdialysis. In addition, we used microdialysis to examine whether MDMA increases free radical formation in the striatum and whether GBR 12909 affects this production. To do this we perfused salicylic acid and measured the formation of 2,3-dihydroxybenzoic acid (2,3-DHBA) as an index of free radical formation (Chiueh et al. 1992 ).
Materials and methods

Animals, drugs and reagents
Male Swiss Webster mice (Harlan Iberica, Barcelona, Spain) weighing 30-35 g were used. They were housed in groups of 10, in standard cages (38 · 22 · 15 cm), in conditions of constant temperature (21 ± 2°C) and a 12-h light/dark cycle (lights on: 07.00h) and given free access to food and water.
(±)-MDMA HCl was obtained from NIDA (Research Triangle Park, NC, USA) and GBR 12909 was obtained from Research Biochemicals Inc. (Natick, MA, USA). Both compounds were dissolved in 0.9% w/v NaCl (saline) and injected i.p. in a volume of 10 mL/kg. Doses are quoted in terms of the base. Control animals were injected with saline.
All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1985) .
Implantation of the microdialysis probe in the striatum The mice were anaesthetized with sodium pentobarbitone (EutaLender, 40 mg/kg, i.p.) and secured in a Kopf stereotaxic frame (model 900) coupled to a Kopf mouse adapter (model 921). The dialysis probe (2.0 mm · 200 lm; Cuprophan) was implanted in the right striatum + 0.7 mm anteroposterior and ) 2.0 mm mediolateral from the bregma and ) 6.0 mm dorsoventral from the surface of the brain (Franklin and Paxinos 1997) . The probe was secured to the skull with one screw and dental acrylic cement, as described by Baldwin et al. (1994) .
Measurement of dopamine and its metabolites in the striatal dialysate Catechol formation in the brain in vivo was measured using the method recently described in detail by Colado et al. (1999) . Twentyfour hours after implantation the probes were perfused with artificial cerebrospinal fluid (aCSF; KCl 2.5 mM; NaCl 125 mM; MgCl 2 .6H 2 O 1.18 mM; CaCl 2 .2H 2 O 1.26 mM) at a rate of 1 lL/min and samples were collected from the freely moving animals at 30-min intervals in tubes containing 5 lL of a solution composed of HClO 4 (0.01 M), cysteine (0.2%) and sodium metabisulfite (0.2%). The first 60-min sample was discarded and the next two 30-min baseline samples collected. A group of animals was perfused with a low calcium aCSF in which the concentration of CaCl 2 .2H 2 O was reduced to 0.1 mM.
Dopamine, DOPAC and HVA were measured in the dialysate by HPLC and electrochemical detection. The mobile phase consisted of KH 2 PO 4 (0.05 M), octanesulfonic acid (0.4 mM), EDTA (0.1 mM) and methanol (16%) and was adjusted to pH 3 with phosphoric acid, filtered and degassed. The flow rate was 1 mL/min. The HPLC system consisted of a pump (Waters 510) linked to a manual sample injector (Loop 20 lL Rheodyne), a stainless steel reversed-phase column (Spherisorb ODS2, 5 lm, 150 · 4.6 mm) fitted with a precolumn, and a coulometric detector (Coulochem 5100A) with a 5011 analytical cell. The working electrode potential was set at 400 mV with 500 nA gain. The current produced was monitored using a computer data handling system (AXXIOM 747).
Measurement of dopamine in striatal tissue
The mice were killed by cervical dislocation and decapitation 7 days after MDMA injection, the brains were rapidly removed and the striatum was dissected out on ice. The tissue was homogenized in a mixture of HClO 4 (0.2 M), cysteine (0.1%), sodium metabisulfite (0.1%) and EDTA (0.01%) and centrifuged at 4°C and 12 000g for 20 min. The dopamine concentration was measured in the supernatant by HPLC. The mobile phase consisted of KH 2 PO 4 (0.05 M), octanesulfonic acid (0.16 mM), EDTA (0.1 mM) and methanol (14%) and was adjusted to pH 3 with phosphoric acid, filtered and degassed. The flow rate was 1 mL/min and the working electrode potential was set at + 0.8 V.
The HPLC system consisted of a pump (Waters 510) linked to an automatic sample injector (Loop 200 lL, Waters 712 WISP), a stainless steel reversed-phase column (Spherisorb ODS2, 5 lm, 150 · 4.6 mm) fitted with a pre-column, and an amperometric detector (Waters M460). The current produced was monitored using an integrator (Waters M745).
Measurement of free radical formation in vivo using microdialysis Free radical formation in the brain in vivo was measured using the method recently described in detail by Colado et al. (1997) with some modifications. The method relies on the fact that hydroxyl free radicals react with salicylic acid to generate 2,3-DHBA and 2,5-DHBA and this reaction is utilized by measuring the formation of these compounds in the dialysate of a microdialysis probe implanted in the striatum (see above) which is being perfused with salicylic acid (Chiueh et al. 1992; Giovanni et al. 1995) . As 2,5-DHBA is also formed peripherally through salicylate hydroxylation by the cytochrome P450 system, only the 2,3-DHBA concentration in the dialysate can be considered a reliable marker of hydroxyl radical formation in the striatum (Halliwell et al. 1991) . Twenty-four hours after implantation, the probes were perfused with aCSF (KCl 2.5 mM; NaCl 125 mM; MgCl 2 .6H 2 O 1.18 mM; CaCl 2 .2H 2 O 1.26 mM; NaH 2 PO 4 .H 2 O 0.5 mM; Na 2 HPO 4 .2H 2 O 5 mM; pH 6.55) containing salicylic acid (2.5 mM) at a rate of 1 lL/min and samples were collected from the freely moving animals at 30-min intervals. The first 60-min sample was discarded and the next two 30-min baseline samples were collected.
The HPLC system consisted of a pump (Waters 510) linked to a manual sample injector (Loop 20 lL Rheodyne), a stainless steel reversed-phase column (250 · 4.6 mm, 5 lm C8 Ultracarb, Phenomenex) fitted with a pre-column (30 · 4.6 mm, 5 lm C8 Ultracarb, Phenomenex), and a coulometric detector (Coulochem 5100A) with a 5011 analytical cell. The working electrode potential was set at 400 mV with 1 lA gain. The mobile phase consisted of KH 2 PO 4 (0.025 M), acetonitrile (20%) and methanol (10%) and was adjusted to pH 3.25 with phosphoric acid, filtered and degassed. The flow rate was 1 mL/min. The current produced was monitored using a computer data handling system (AXXIOM 747).
Measurement of tissue lipid peroxidation
Lipid peroxidation was measured using a modification of the method of Das and Ratty (1987) , whereby the thiobarbituric acidreacting substances, predominantly malondialdehyde, produced as a secondary product were quantified using the 2-thiobarbituric acid colour reaction. Striatal tissue was homogenized in 50 vol of sodium phosphate buffer 50 mM (pH 7.4) and diluted to produce a tissue concentration of 11 mg/mL. The assays contained 500 lL of tissue homogenate, 150 lL of HCl (0.5 M), 300 lL of trichloroacetic acid (40% v/v) and 300 lL of 2-thiobarbituric acid (2% w/v). The samples were heated for 15 min at 90°C and centrifuged at 10 000g at 4°C for 10 min. The pink colour developed by the reaction was measured by recording optical density at 532 nm and the malondialdehyde concentration was calculated using a standard curve prepared with malondialdehyde tetrabutylammonium salt.
FeCl 2 + ascorbic acid-induced lipid peroxidation in vitro
To determine whether GBR 12909 had free radical scavenger activity, we evaluated the effect of GBR 12909 on brain lipid peroxidation in vitro. Mice cortical synaptosomes (P2 fraction) were prepared as described by Lynch and Voss (1990) and resuspended in Tris buffer 50 mM (pH 7.4) containing 120 mM NaCl and 5 mM KCl to produce a protein concentration of approximately 400 lg/mL. Membranes (400 lL) were added to 50 lL of FeCl 2 (30 lM), 50 lL of ascorbic acid (1 mM) and 50 lL of GBR 12909 (1-100 lM final concentration) and incubated at 37°C for 30 min. Tubes containing the free radical scavenger butylated hydroxytoluene (BHT; 0.1-100 lM final concentration) were also included as a positive control. Lipid peroxidation was measured in the incubation mixture as described above. The experiments were performed at least three times for each compound and the assays were performed in triplicate.
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Measurement of GBR 12909 and MDMA concentration in striatal tissue Brain concentrations of GBR 12909 and MDMA were determined following a previously described method with minor modifications . The striatal tissue was homogenized in ice-cold sodium carbonate-sodium bicarbonate buffer (pH 11.5) using an ultrasonicator. The homogenate was centrifuged at 27 000g for 20 min at 4°C. The supernatant was applied to a 145-mg C8 end-capped SPE light column (International Sorbent Technology, Waters). The column was washed with methanol (2 mL) followed by distilled water (2 mL) before applying the sample (400 lL of supernatant + 350 lL of distilled water). The column was washed with water (2 mL) before selective elution of GBR 12909 or MDMA with methanol (1 mL).
An aliquot (20 lL) of the resulting eluate was injected into a Waters HPLC system which consisted of a pump (Waters 510) linked to a manual sample injector (Loop 20 lL, Rheodyne), a stainless steel column (RP 18, 5 lm, 150 · 4.6 mm, XTerra) fitted with a pre-column (RP 18, 5 lm, 20 · 3.9 mm, XTerra), and a UV/ visible detector (Waters 2487). The current produced was monitored using an integrator (Waters M745). For GBR 12909 analysis the mobile phase consisted of 20 mM potassium dihydrogen phosphate (55%) and acetonitrile (45%), pH 2.5; the flow rate was set to 1.0 mL/min and UV absorption was measured at 200 nm. The retention time was 8.3 min. For MDMA analysis the mobile phase consisted of 20 mM potassium dihydrogen phosphate (75%) and acetonitrile (25%), pH 2.5; the flow rate was set to 0.8 mL/min and UV absorption was measured at 235 nm. The retention times were 5.1 min for MDMA and 6.4 min for 3,4-methylenedioxyethylamphetamine (internal standard). In each run, GBR 12909 and MDMA peaks were completely resolved without any interference from endogenous compounds. Recovery was determined by comparing the peak height ratios of the extracted standards with those obtained by direct injection of the non-extracted standard in the range 2-16 lg/mL for GBR 12909 and 5-80 lg/mL for MDMA. The limit of detection under the described conditions was 10 pg/lL with a signal-to-noise ratio of 3 : 1. Intra-assay variation was less than 5% and recovery was greater than 95% for GBR 12909 and 60% for MDMA.
Measurement of rectal temperature
Temperature measurement was performed using a digital readout thermocouple (Type K thermometer, Portec, UK), with a resolution of ± 0.1°C and an accuracy of ± 0.2°C, attached to a CAC-005 rodent sensor. The probe was inserted 2 cm into the rectum of the mouse while the animal was lightly restrained by holding in the hand. A steady readout was obtained within 10 s of probe insertion.
Statistics
Statistical analyses of the microdialysis experiments were performed using the statistical computer package BMDP/386 DYNAMIC (BMDP Statistical Solutions, Cork, Ireland) . The data were analysed by means of a two-way ANOVA with repeated measures (program 2V) or, where missing values occurred, an unbalanced repeated measures model (program 5V) was used. Both used treatment as the betweensubjects factor and time as the repeated measure. The ANOVA was performed on both pre-and post-treatment data. The data from the lipid peroxidation experiment in striatal tissue were analysed using a one-way ANOVA followed by the Tukey multiple comparison test when a significant F-value was obtained (GraphPad Prism, San Diego, CA, USA).
Results
Changes in dopamine metabolism following MDMA administration and the effect of GBR 12909 The administration of MDMA (30 mg/kg, i.p.), three times at 3-h intervals, produced a rapid increase in the extracellular concentration of dopamine in the striatal dialysate, a peak occurring 1 h after each of the three injections (Fig. 1a) . This effect was accompanied by a sustained decrease in both HVA and DOPAC, the decrease in the latter starting earlier than that of the former (DOPAC and HVA levels compared with basal values were 44 ± 5 and 82 ± 6%, respectively, 1 h after MDMA) (Figs 1c and d) .
GBR 12909 (10 mg/kg, i.p.) given 30 min before each MDMA injection potentiated the MDMA-induced effect on extracellular dopamine, thereby enhancing the size of the total dopamine response (Fig. 1a) and did not alter the MDMA-induced effect on extracellular DOPAC and HVA (Figs 1c and d) .
The injection of GBR 12909 (10 mg/kg, i.p.), three times at 3-h intervals to saline-injected mice, modestly increased extracellular dopamine (Fig. 1b) and decreased extracellular DOPAC (Fig. 1c) , while the HVA concentration was not altered (Fig. 1d) .
Effect of a low calcium medium perfusion on the dopamine release induced by MDMA The fact that pre-treatment with GBR 12909 did not reduce the increase in extracellular dopamine induced by MDMA suggested that the release of dopamine following MDMA was not occurring through the dopamine transporter operating in reverse as the result of MDMA being taken up into the nerve endings via the dopamine uptake system, but through a calcium-dependent exocytotic-like procedure. To investigate this, a group of animals was implanted with a dialysis probe in the striatum and, after baseline samples were collected, they were perfused with a medium in which the calcium concentration was lowered from 1.26 to 0.1 mM. Two hours after the change in perfusion medium, the mice were administered two consecutive doses of MDMA 3 h apart. As shown in Fig. 2(a) , perfusion with a low calcium medium significantly reduced the basal extracellular dopamine levels and clearly reduced the ability of MDMA to increase dopamine release in the striatum. No overt effect of the low calcium medium was seen on the extracellular concentration of the metabolites (Figs 2b and c) .
Formation of 2,3-DHBA in the dialysate following MDMA and the effect of GBR 12909 Repeated administration of MDMA (30 mg/kg, i.p. · 3, every 3 h) produced a rapid and sustained increase in the 2,3-DHBA concentration in the striatal dialysate. The increase in 2,3-DHBA was approximately 40% above the concentration seen in saline-injected mice after the first MDMA injection and 100% above the saline-injected value following the second MDMA injection. This increase was sustained until the end of the experiment (Fig. 3) .
GBR 12909 (10 mg/kg, i.p.), given 30 min before each of the three injections of MDMA, significantly attenuated the MDMA-induced increase in the concentration of 2,3-DHBA in the striatal dialysate. The 2,3-DHBA level in the dialysate of this group was similar to that observed following the administration of GBR 12909 to saline-injected mice (Fig. 3) .
Lipid peroxidation following MDMA administration and the effect of GBR 12909 One hour after repeated administration of MDMA (30 mg/kg, i.p. · 3, every 3 h) there was a 30% increase in malondialdehyde formation in the homogenate prepared from striatum (Fig. 4) . GBR 12909 (10 mg/kg, i.p.), given 30 min before each of the three MDMA injections, significantly attenuated (60%) the increase in malondialdehyde formation. No change in lipid peroxidation was observed in the striatal homogenate when GBR 12909 was given to saline-injected mice (Fig. 4) .
Effect of GBR 12909 on FeCl 2 + ascorbic acid-induced lipid peroxidation in vitro Because GBR 12909 attenuated both the increase in the 2,3-DHBA concentration in the striatal perfusate and the increase in peroxidation in striatal tissue that followed MDMA administration, we next examined whether this resulted from GBR 12909 having free radical trapping activity.
Incubation of cortical synaptosomes from untreated animals with FeCl 2 /ascorbate resulted in an approximate 400% increase in malondialdehyde formation (8.6 ± 1.5 nmol malondialdehyde/mg protein increasing to 33.1 ± 2.3 nmol malondialdehyde/mg protein). The free radical scavenger BHT inhibited the peroxidation-induced increase in a concentration- MDMA on extracellular dopamine (F 1,18 ¼ 11.48, p < 0.001) and did not produce any change in DOPAC (F 1,13 ¼ 2.64, NS) and HVA (F 1,13 ¼ 0.24, NS) levels. GBR 12909 given to saline-treated mice produced an increase in the extracellular levels of dopamine (F 1,13 ¼ 25.51, p < 0.001) and a decrease in the content of DOPAC (F 1,17 ¼ 5.78, p < 0.05). Values are expressed as a percentage of the mean of two measurements before drug administration. Each value is the mean ± SEM of between seven and 11 experiments. The basal concentrations in saline-treated mice were: dopamine 0.93 ± 0.2 pg/lL; DOPAC 42 ± 7 pg/lL and HVA 76 ± 11 pg/lL. Ecstasy, dopamine release and free radicals 965 dependent way with an ED 50 of 1.32 lM. GBR 12909 was also weakly active as a radical trapping agent and inhibited malondialdehyde production. However, it was approximately 25 times less potent than BHT at inhibiting malondialdehyde production, having an ED 50 of 32.8 lM (Fig. 5) . Fig. 2 Changes in the levels of (a) dopamine, (b) 3,4-dihydroxyphenylacetic acid (DOPAC) and (c) homovanillic acid (HVA) in the striatal dialysate of mice perfused through the probe with a medium of low calcium concentration (0.1 mM). After three baseline samples had been collected, the artificial cerebrospinal fluid (aCSF) was changed to another containing a 0.1 mM calcium concentration. Two hours later the mice received 3,4-methylenedioxymethamphetamine (MDMA; 30 mg/kg, i.p. · 2, 3 h apart). Perfusion with 0.1 mM calcium-containing aCSF produced a reduction in the basal levels of dopamine (F 1,14 ¼ 5.43, p < 0.05). The MDMA-induced increase in extracellular dopamine concentration was reduced in the dialysate from mice perfused with a low calcium-containing aCSF (F 1,14 ¼ 21.32, p < 0.001). Values are expressed as a percentage of the mean of three measurements before the aCSF changed. Each value is the mean ± SEM of between seven and 11 experiments. The basal concentrations in saline-treated mice were: dopamine 0.70 ± 0.1 pg/lL; DOPAC 55 ± 10 pg/lL and HVA 93 ± 16 pg/lL. GBR 12909 concentration in the striatum following its i.p. administration To examine whether the concentration of GBR 12909 following i.p. administration would be sufficient to act as a radical trapping agent, we examined its concentration in the striatum. The mice were injected with GBR 12909 (10 mg/kg · 3, every 3 h) and killed 30 and 60 min after the last injection. The striatal concentrations of GBR 12909 were observed to be 2.1 ± 0.2 (n ¼ 8) and 1.7 ± 0.1 lM (n ¼ 8), respectively, at these times.
Long-term MDMA-induced dopamine loss and the effect of GBR 12909
The repeated administration of MDMA (30 mg/kg, i.p. · 3, every 3 h) produced a decrease in the striatal dopamine concentration 7 days later (Table 1) . GBR 12909 (10 mg/kg · 3, every 3 h), given 30 min before each of the three injections of MDMA, completely prevented the MDMA-induced loss in dopamine content (Table 1) .
Changes induced by MDMA on rectal temperature and the effect of GBR 12909 MDMA (30 mg/kg, i.p. · 3, every 3 h) induced a pronounced hyperthermic response after the first and second injections (Fig. 6) . Pre-treatment with GBR 12909 (10 mg/kg · 3, every 3 h) did not alter the increase in body temperature seen after each of the first two injections of MDMA (Fig. 6) .
Effect of GBR 12909 on striatal levels of MDMA In order to investigate the possible effect of GBR 12909 on the concentration of MDMA in the brain, the mice were given saline or GBR 12909 (10 mg/kg, i.p.) 30 min before each of the three MDMA injections (30 mg/kg, i.p.) and killed 1 h later. This time point was chosen because the cerebral concentration of MDMA normally peaks 60 min after MDMA injection ). There were no differences between the MDMA levels found in the striatum of mice pre-treated with GBR 12909 (38 ± 5 nmol/g tissue, n ¼ 8) and those injected with saline (36 ± 2 nmol/g tissue, n ¼ 8).
Discussion
In a previous study we demonstrated that when the dopamine uptake inhibitor GBR 12909 was injected before each dose of MDMA (30 mg/kg i.p.) given three times at 3-h intervals, it abolished the substantial loss in striatal dopamine concentration that occurs 7 days following administration of this amphetamine derivative. This effect was confirmed in the current study (Table 1) . It is probable Ecstasy, dopamine release and free radicals 967 that this long-term loss in dopamine reflects a neurotoxic degeneration of dopamine nerve terminals in this brain region (Mann et al. 1997) .
Studies on the acute changes in tissue dopamine and its metabolites indicated that GBR 12909 was not blocking the acute dopamine-releasing action of MDMA, but, if anything, was enhancing this effect . This, in turn, suggested that GBR 12909 was not preventing the entry of MDMA into the dopamine nerve endings. We have now obtained direct evidence for this proposal by the use of in vivo microdialysis. GBR 12909 administration enhanced the extracellular dopamine concentration following each MDMA injection, thereby confirming our earlier interpretation that GBR 12909 does not block the ability of MDMA to release dopamine . GBR 12909 alone also produced a small increase in extracellular dopamine. It has been suggested (Westerink et al. 1987; Miller and Abercrombie 1999) that GBR 12909 when given alone elicits an increase in extracellular dopamine and a decrease in DOPAC because it decreases the amount of dopamine that is catabolized by monoamine oxidase as a result of the smaller amount of dopamine re-entering the nerve terminal to be stored in the vesicles.
One reason for the failure of GBR 12909 to inhibit MDMA uptake into the dopamine nerve endings could be that it had been given at a dose too low to block the transporter. However, the IC 50 value of GBR 12909 for inhibiting dopamine uptake is between 10 and 50 nM (Heikkila and Manzino 1984; Jacocks et al. 1991) and our data suggest that much higher concentrations were achieved in the brain in our experiments. In addition, Rothman et al. (1991) suggested the ED 50 dose for inhibiting the transporter to be 10 mg/kg and this dose of GBR 12909, which was also used in the current study, has previously been shown to be sufficient to block the dopamine-releasing effect of methamphetamine (Stephans and Yamamoto 1994) .
Thus, the current findings indicate that GBR 12909 does not prevent the entry of MDMA into the pre-synaptic nerve terminal and therefore support the contention that MDMA probably penetrates by passive diffusion, as previously suggested . In addition, the fact that the blockade of the dopamine transporter by GBR 12909 failed to reduce the effect of MDMA on dopamine outflow suggests that dopamine is released by a mechanism not related to the dopamine transporter. This proposal is supported by our observation that the MDMA-induced release of dopamine was markedly reduced by the removal of calcium from aCSF perfused through the microdialysis probe.
Taken together the GBR 12909 study and the calcium concentration study indicate that the massive release of dopamine into the synaptic cleft induced by MDMA administration is the result of an exocytotic-like process and not a consequence of the uptake of MDMA by the dopamine transporter and reversal of the pump.
As reviewed in the introduction, there is evidence using transgenic mice that the neurotoxicity following MDMA administration to mice results from free radical-induced damage (Cadet et al. 1995; Jayanthi et al. 1999) . The current study has now provided direct evidence for this contention by using in vivo microdialysis. Following MDMA administration, the conversion of salicylic acid to 2,3-DHBA was increased. This increase was enhanced and sustained by the further administration of MDMA. It is worth pointing out that when MDMA is given at a dose of 30 mg/kg, significant damage to striatal dopamine occurs only after the second and further doses of the drug . The elevated levels of hydroxyl radicals lead to an increase in the degree of striatal lipid peroxidation (reflected by an increase in malondialdehyde production), indicating that oxidative stress is involved in the tissue damage of MDMA.
Interestingly, the dopamine uptake inhibitor GBR 12909, co-administered with MDMA, attenuated both the MDMA-induced increase in the 2,3-DHBA concentration in the dialysate and the increase in malondialdehyde formation. Shankaran et al. (1999a) similarly reported that the dopamine uptake inhibitor mazindol also decreased MDMAinduced 2,3-DHBA formation in the rat.
While there is considerable evidence to show that GBR 12909 selectively binds to the dopamine transporter, inhibiting neurotransmitter uptake (Heikkila and Manzino 1984; Andersen 1989; Nissbrandt et al. 1991) , no data are available as to whether this compound also has free radical trapping activity. For that reason, the current study evaluated the effect of GBR 12909 on non-enzymatic lipid peroxidation in vitro mediated by ascorbic acid and iron. Although the compound was far less potent than BHT, GBR 12909 did inhibit the FeCl 2 /ascorbic acid-stimulated lipid peroxidation in cortical synaptosomes at a concentration of 20 lM or higher. In order to determine whether the antioxidant activity of GBR 12909 could be contributing to its ability to reduce the MDMAinduced increase in hydroxyl radical formation, the striatal concentration of GBR 12909 was determined following the last injection. The data showed that the concentration of GBR 12909 found in striatal tissue (approximately 2 lM) after systemic administration was unlikely to be sufficient to produce a free radical scavenging action of functional significance.
The fact that GBR 12909 enhanced the extracellular dopamine concentration observed immediately after MDMA administration, but nevertheless also decreased free radical and malondialdehyde formation and protected against the MDMA neurotoxic damage , suggests that free radicals and oxidative stress are involved in MDMA-induced neurotoxicity. It also suggests that the enhanced dopamine release is not a key mechanism involved in the production of the damage. This interpretation in turn impinges on any discussion as to the source of hydroxyl radical formation. There is abundant experimental evidence showing a relationship between dopamine oxidation and hydroxyl radical generation. In our earlier study we observed that repeated administration of MDMA to mice produced a marked decrease in the content of dopamine in the striatal tissue 3 h later . Using intracerebral microdialysis, the current study confirms and extends these data and shows that immediately after MDMA administration there is a massive increase in the concentration of dopamine in the striatal dialysate which reflects an increase in monoamine release. It is well known that dopamine is a reactive molecule which through enzymatic degradation by monoamine oxidase is transformed intraneuronally into DOPAC and hydrogen peroxide (Cohen 1984) . Hydrogen peroxide in turn, in the presence of a transition metal ion such as ferrous iron and via the Fenton reaction, is prone to producing hydroxyl free radicals (Graham 1978; Cohen 1987; Halliwell 1992; Olanow 1992 ). In addition, by means of auto-oxidation the catechol ring of dopamine is transformed into semiquinones or quinones of dopamine together with reactive oxygen species such as hydrogen peroxide and superoxide anion Coyle and Puttfarcken 1993) . MDMA inhibits the enzymatic degradation of dopamine through an inhibition of monoamine oxidase A activity (Leonardi and Azmitia 1994) which is reflected by a decrease in DOPAC and HVA levels, so the formation of hydroxyl radicals from enzymatic oxidation of dopamine can probably be discounted. Thus, the MDMAinduced increase in hydroxyl radicals could be the result of dopamine auto-oxidation. Nevertheless, our results do not support this contention for the following reasons. It is rather clear that GBR 12909 administered concurrently with MDMA enhanced the dopamine concentration in the synaptic cleft, an effect that can be explained by a summatory effect due to GBR 12909 inhibiting dopamine uptake and concomitantly MDMA increasing the release of dopamine. Nevertheless, when GBR 12909 is co-administered with MDMA it does not potentiate the formation of hydroxyl radicals induced by MDMA but rather partially attenuates it. The fact that GBR 12909 attenuates the content of 2,3-DHBA in the striatal dialysate without reducing the extracellular concentration of dopamine indicates that the main source of MDMA-induced hydroxyl radical formation could not be the catabolism of dopamine.
Until recently there has been significant support for the contention that endogenous dopamine plays an essential role in the production of neurotoxicity following the administration of both MDMA (Nash and Brodkin 1991; Schmidt et al. 1991) and methamphetamine (Gibb et al. 1994) . However, Colado et al. (1999) were unable to demonstrate a role for dopamine in MDMA-induced neurotoxicity, suggesting that the main action of dopaminergic agents was to alter toxicity by changing body temperature. This proposal has now been supported by the study of Yuan et al. (2001) who also questioned the role of endogenous dopamine in methamphetamine-induced neurotoxicity. This group (Yuan et al. 2001) presented data which suggested that earlier evidence for a role of dopamine was confounded by body temperature changes. It is therefore not unreasonable to suggest that the free radicals detected in the current study resulted from MDMA metabolism rather than from dopamine catabolic products.
These data, in turn, have another implication and indirectly indicate that the toxicity of MDMA is not due to the parent compound but to a toxic metabolite which uses the dopamine transporter to get into the terminal and that once inside, initiates the production of free radicals. These results are in agreement with previous studies in rats showing that intracerebral administration of MDMA at a dose that produced a concentration similar to or higher than that reached following a neurotoxic dose of MDMA given peripherally, does not produce neurotoxic damage . MDMA is metabolized into catechol and quinone metabolites (Tucker et al. 1994) . Further metabolism of these compounds could result in the formation of free radicals which may induce oxidative stress and subsequent cellular damage. In addition, we can state with some degree of confidence that GBR 12909 does not prevent MDMA neurotoxicity by inhibiting the metabolism of the drug, as the dopamine uptake inhibitor did not alter the concentration of MDMA in the brain. Furthermore, and confirming earlier observations , an involvement of temperature in the neuroprotective effect of GBR 12909 may be ruled out as GBR 12909 did not alter the hyperthermic response induced by MDMA.
It is noteworthy that, in rats, the 5-HT uptake inhibitor fluoxetine prevents the increase in free radical formation that follows MDMA (Shankaran et al. 1999b ) and also prevents the subsequent neurodegeneration of 5-HT nerve endings . In mice, we have now shown that the dopamine uptake inhibitor GBR 12909 attenuates both the acute increase in free radicals and lipid peroxidation produced by MDMA administration and also prevents the long-term neurotoxic damage to dopamine nerve endings. Our results differ from those showing that cocaine, an inhibitor of the dopamine transporter on the pre-synaptic dopaminergic terminals, completely fails to protect against MDMA toxicity in mice . This discrepancy could be attributed to the fact that the pharmacokinetic profile of cocaine is different from that of GBR 12909 in that it shows a short biological half-life and therefore a fast dissociation from the dopamine transporter (Tsukuda et al. 2000) .
In conclusion these data indicate that the dopamine transporter is involved in the generation of hydroxyl free radicals and long-lasting dopamine neurotoxicity of MDMA in mice, but not in the acute release of dopamine evoked by MDMA. 
